Agency / Source: GenScript Corporation

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Legend Biotech Announces Closing of Global Strategic LCAR-B38M Car-T Cell Immunotherapy Collaboration with Janssen - Legend Biotech announced it has executed a strategic collaboration agreement to jointly develop and commercialize the LCAR-B38M based products with Janssen Biotech, Inc. (
Legend Biotech Announces Closing of Global Strategic LCAR-B38M Car-T Cell Immunotherapy Collaboration with Janssen

 

PRZOOM - /newswire/ - Nanjing, Jiangsu, China, 2018/02/22 - Legend Biotech announced it has executed a strategic collaboration agreement to jointly develop and commercialize the LCAR-B38M based products with Janssen Biotech, Inc. ("Janssen") - Janssen.com / LegendBiotech.com / GenScript.com. 1548:HK

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

• Legend to receive an upfront payment of $350 million, as well as additional development, production performance, regulatory and sales milestone payments;
• Legend and Janssen to co-develop and co-promote CAR-T cell therapy for multiple myeloma;
• Profits and costs to be shared 50/50 worldwide, exclusive Greater China where 70 percent to Legend and 30 percent to Janssen.

Legend Biotech, a subsidiary of GenScript Biotech Corporation that develops innovative Car-T cell immunotherapy targeting Multiple Myeloma, announced today it has executed a strategic collaboration agreement to jointly develop and commercialize the LCAR-B38M based products with Janssen Biotech, Inc. ("Janssen").

According to the terms of the agreements, the companies have agreed to jointly share the development, production and commercialization activities, with a 50/50 profit-loss sharing agreement for the world-wide market excluding Greater China. Legend Biotech and Janssen (janssen.com) enters a 70/30 profit-loss sharing agreement for Greater China market. Legend Biotech will receive an upfront payment of $350 million from Janssen, and will be eligible for additional payments upon development, production performance, regulatory and sales milestones.

"This is a very important milestone for Legend Biotech. LCAR-B38M is the first CAR-T accepted for review by the national Health Authority CFDA in China. We are very pleased to work with Janssen to co-develop and co-commercialize the product worldwide. Janssen, is a leading pharmaceutical company which has a proven track-record to establish successful collaboration and bring transforming therapies into the market. We look forward to working with Janssen to transform the multiple myeloma therapies and bring hopes to multiple myeloma patient worldwide." said Frank Zhang, Ph.D., Chairman of Legend Biotech.

About LCAR-B38M
LCAR-B38M is a type of bi-epitope Chimeric Antigen Receptor T cell (CAR-T) immunotherapy developed by Legend Biotech Corporation. Autologous T cells isolated from patients can be genetically engineered to express bi-epitope chimeric antigen receptors on their surface, so that allows the autologous T cells to specifically recognize and bind the two epitopes on BCMA molecule that is a biomarker of Multiple Myeloma (MM). Therefore the autologous genetically engineered T cells are able to specifically identify and kill the MM cancer cells.

About Legend Biotech Corporation
Legend Biotech (legendbiotech.com) is a subsidiary of GenScript Biotech Corporation, with its global presence in the United State, Hong Kong, Ireland and Nanjing China. Legend Biotech engages and concentrates on the construction of CAR-T cell therapy platform, and it has built up its own proprietary intellectual property position. Its LCAR-B38M based products have demonstrated outstanding overall response rate (ORR) in a series of pre-clinical studies treating refractory Multiple Myeloma. At present, around 140 employees globally located have been committing in continuous research and development process aiming to provide revolutionary Car-T cell therapies to cancer patients.

About GenScript Biotech Corporation
Genscript Biotech Corporation (genscript.com) serves as a partner for researchers in basic life sciences, translational and biomedical fields as well as early-stage drug development, the diverse portfolio of GenScript encompasses extensive services in gene synthesis and molecular biology, peptide synthesis, protein expression and engineering, custom antibody development and engineering, in vitro/in vivo pharmacology as well as variety of catalogue products. Two other business divisions, under the brand name of Bestzyme Biotech and Legend Biotech engaged in Industrial Enzymes and Car-T Cell Immunotherapy respectively have both made rapid progress and breakthrough in their respective business development.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: GenScript Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Legend Biotech Announces Closing of Global Strategic LCAR-B38M Car-T Cell Immunotherapy Collaboration with Janssen

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
GenScript Biotech Corp. | Janssen
Contact: Sally Wang - GenScript.com 
732-885-9188 x111 sally.wang[.]genscript.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GenScript Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From GenScript Corporation / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

DSM Expands Animal Nutrition & Health Operations in China with Opening of Seventh Premix Plant
Biosurfactants and Natural Preservatives Drive Innovation for Functional Ingredients in Personal Care Market Finds Frost & Sullivan
Ypsomed Collaborates with SCHOTT and Lonza to Develop A Comprehensive Solution for Combination Products Based on Patch Injectors
DSM Unveils Purpose-led Brand Strategy Marking Transition to End-to-end Partner in Nutrition and Health
Ipsen to Present 12 Abstracts At the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress
Imec Announces elPrep5 - the Newest Version of its Software Platform for DNA Analysis
Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  Calmerry

Visit  JobsWare.com

Visit  RightITnow, Inc.







 
  ©2020 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today